Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07747896

Effect of a Coordinated Primary-care-Based MDT-model on the Treatment of Hard-to-heal Ulcers

The TSS project is a study of the effects of treating hard-to-heal ulcers in a multidisciplinary cross sectional team, meaning that nurse and doctor from a hospital based wound healing clinic and wound care nurse from the primary care sector treat the patient in collaboration rather than the current form where care in municipalities and hospital setting, communicate but treat the patient on their own. The study is designed as a randomized study, meaning that individuals with hard-to-heal ulcers are randomly designated to standard care or the multidis-ciplinary team. We measure several aspects of the new format, but the main outcome com-pared between the two groups (standard care and multidisciplinary care) is number of ulcers healed.

Participants are followed for a year after inclusion in the study, and have 6 fixed visits in the clinic, with the possibility of more visits if necessary.

There is no "new" medicine, surgery or other treatments planned in the study, but the multi-disciplinary team can offer and implement any treatment deemed appropriate for the individ-ual that is allocated to the multidisciplinary team, of course the individual has the opportunity to decline any treatment offered by the team. The control group, i.e. individuals allocated to standard care, will receive the treatment that is normally available to individuals with hard-to-heal ulcers treated in the municipality, including referral to hospital based treatments.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

North Zealand Hospital

Hillerød, 3400, Denmark

Location status: Recruiting

Location contact

Jonas Askø Andersen, Md Phd Clin Assoc Prof

CONTACT

[email protected]

+4523258084

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 18 years or above
  • Hard-to-heal ulcer(s)
  • Able to understand written and oral information
  • Ability to follow planned visits and treatment
  • Able to provide informed consent in Danish and/or English

Exclusion criteria

Revascularization procedure in the affected limb planned, or undertaken within the 4 weeks prior to screening

  • Toe blood pressure < 35mmHg
  • Infections of the ulcer needing acute or sub-acute (defined as within seven days) surgical treatment
  • Prior major amputations on affected or contralateral leg
  • Current treatment with cytotoxic drugs or with systemically administered glucocorticoids
  • Likely inability to comply with the need for planned visits because of planned activities
  • Participation in another interventional ulcer-healing trial within the 4 weeks prior to screening
  • Prior enrolment in this trial
  • Judgement by the investigator that the patient does not have the capacity to understand the study procedures or provide written informed consent

Treatment and study plan

coordinated primary-care-based MDT-model

Other

The proposed intervention consists of an MDT with an orthopedic surgeon (Jonas Askø Andersen) and a wound care nurse from the wound clinical at North Zealand Hospital as well as a wound care nurse from the primary sector. Participants who are randomized to intervention is offered treatment in the team as deemed appropriate by the MDT. The participant will be seen in the clinic (in the primary sector) for planned study visits at.

  • Week 1 2. Week 4 3. 3 months 4. 6 months 5. 12 months 6. Extra study visits can be planned as deemed necessary for the individual participant between the above outlined visits Weekly visits in the clinic for bandage changes and standard wound care is planned as deemed relevant by the MDT team for the individual participant. The visits are performed by wound care nurses in the primary sector If any outcomes relevant for the study occurs outside of the planned study visits i.e., ulcer healing, infections or recurrence following

Standard Care (in control arm)

Other

Participants randomized to control are not invited to be seen by the MDT team but are attended by the wound care nurse from the primary sector as part of the standard treatment offered to individuals with ulcers in the municipality. Apart from planned visits at 3, 6 and 12 months, the frequency and number of visits in the study period is performed as deemed appropriate by the wound care nurses from the primary sector. If any outcomes relevant for the study occurs outside of the planned study visits i.e., ulcer healing, infections or recurrence following healing date of event is noted.

Primary outcomes

  1. Ulcer healing

    Time frame: Ulcer healing at 12 months

    Number of individuals that achieve healing of their hard-to-heal ulcer(s), compared between two arms

Secondary outcomes

  1. Time to ulcer healing

    Time frame: 12 moths

    Mean time (in days) to healing of healed hard-to-heal ulcer(s) in days - compared between groups

  2. Ulcer recurrence

    Time frame: 12 months

    Incidence of recurrence of ulcer following healing of hard-to-heal ulcer(s) - compared between groups

  3. Infections

    Time frame: 12 months

    Incidence of infections divided in

    • Infection treated with tablet antibiotic
    • Infection treated with intravenous antibiotics, admittance to hospital and/or surgery Compared between groups
  4. Amputations

    Time frame: 12 months

    Incidence and amputations in total and divided in

    • Below ankle amputation
    • Above ankle amputations Compared between groups
  5. Visits

    Time frame: 12 months

    Number of visits to clinics due to hard-to-heal ulcer(s) - compared between groups

  6. Hospital admissions

    Time frame: 12 months

    Days admitted to hospital due to hard-to-heal ulcer(s) - compared between groups

  7. Patient related outcomes

    Time frame: 12 months

    Patient related outcomes (Wound-QoL) - compared between groups Wound-Qol is a PROM tool designed for patients living with chronic ulcers, and is scored on 17-items, from 0 to 4 for each item. The higher the score the worse the outcome. The scores are registered as a global score for all 17 items and divided in three subscales.

  8. Cost effectiveness

    Time frame: 12 months

    Cost effectiveness of intervention will be assessed by comparing expenditures between intervention and control group at four levels;

    • Hospital based care: Calculated using yearly Diagnosis Related Group (DRG) rates determined by the Danish Health Data Authority, obtained from the Danish National Patient Register
    • Primary care: Calculated using fees paid to healthcare providers by the health management regions, including general practitioners, podiatrists, and other specialists in primary care.
    • Prescribed medication: Calculated as the total cost of medication, including any out-of-pocket expenses, obtained from the Danish National Prescription Registry
    • Municipal home care: Calculated based on the average number of minutes of home care provided weekly, summed to total monthly hours. These hours are multiplied by the average hourly cost found in the national database of municipal services Were cost are not directly discernable from the above mentioned data sources estimates of
  9. RE-AIM

    Time frame: 12 months

    RE-AIM outcomes will be applied to assess implementation outcomes and is divided in five domains (first given here)

    o Reach will be assessed using data available from Frederikssund Kommune on number of individuals with hard-to-heal ulcer(s) treated that can be reached with the cross-sectional MDT intervention in the municipality.

  10. RE-AIM

    Time frame: 12 months

    RE-AIM outcomes will be applied to assess implementation outcomes and is divided in five domains (second given here)

    o Effect will be assessed by the clinical outcomes described above i.e., ulcer healing, infection etc.

  11. RE-AIM

    Time frame: 12 months

    RE-AIM outcomes will be applied to assess implementation outcomes and is divided in five domains (third given here)

    o Adoption will be assessed on a local (NOHs catchment area), regional (the Capital Region of Denmark) and on a Danish level, by the number of clinics that have adopted the cross-sectional MDT model.

  12. RE-AIM

    Time frame: 12 months

    RE-AIM outcomes will be applied to assess implementation outcomes and is divided in five domains (fourth given here)

    o Implementation will be assessed by the proportion of eligible individuals with hard-to-heal-ulcers offered the MDT-approach in Frederikssund Kommune.

  13. RE-AIM

    Time frame: 12 months

    RE-AIM outcomes will be applied to assess implementation outcomes and is divided in five domains (fifth given here)

    o Maintenance will be assessed by how many of the clinics that have adopted the intervention actually maintain the intervention over time.

Study contacts

Contact information is provided by the study sponsor or research team.

Jonas Askø Andersen, Md Phd Clin Assoc Prof

CONTACT

[email protected]

+4548297451

Sponsors and collaborators

Lead sponsor

Nordsjaellands Hospital

Other

Collaborators

  • Frederikssund Municipality, Denmark

Registry information

Official study title

Effect of a Coordinated Primary-care-Based MDT-model on the Treatment of Hard-to-heal Ulcers; a Randomized Clinically Controlled Trial

Acronym: TSS

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Aug 5, 2026
Registry last updated
Aug 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.